Warfarin vs. Asprin in Reduced Ejection Fraction
Warfarin vs. Asprin in Reduced Ejection Fraction
Warfarin vs. Asprin in Reduced Ejection Fraction
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Warfar<strong>in</strong></strong> <strong>vs</strong>. Aspir<strong>in</strong> Hazard Ratios by Year of Follow-up*<br />
(Prespecified Time-Vary<strong>in</strong>g Analysis)<br />
Hazard Ratio for <strong>Warfar<strong>in</strong></strong> versus Aspir<strong>in</strong><br />
2.0<br />
1.8<br />
1.6<br />
1.4<br />
1.2<br />
1.0<br />
0.8<br />
0.6<br />
0.4<br />
0.2<br />
0.0<br />
Aspir<strong>in</strong><br />
better<br />
<strong>Warfar<strong>in</strong></strong><br />
better<br />
Significant Treatment by Time Interaction:<br />
HR multiplier per year: 0.894 (0.800, 0.998), p=0.046.<br />
0 1 2 3 4 5 6<br />
Year<br />
Aspir<strong>in</strong> 1073 860 658 508 329 94<br />
<strong>Warfar<strong>in</strong></strong> 1049 852 653 525 363 115<br />
*Estimated from time-vary<strong>in</strong>g model <strong>in</strong> cont<strong>in</strong>uous time
Change language